Immunotherapeutic strategies for the treatment of plasma cell malignancies

Seminars in Oncology

Volumn 27, Issue 5, 2000, Pages 598-613

  Treon, S P ^a   Raje, N ^a   Anderson, K C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD19 ANTIGEN; CD20 ANTIGEN; CD38 ANTIGEN; DEXAMETHASONE; DNA VACCINE; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; RITUXIMAB; TUMOR VACCINE;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONFERENCE PAPER; DRUG TARGETING; HUMAN; MALIGNANT PLASMACYTOMA; MULTIPLE MYELOMA; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; RECEPTOR UPREGULATION; VACCINATION;

CANCER VACCINES; CLINICAL TRIALS; HUMAN; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY, ACTIVE; IMMUNOTHERAPY, ADOPTIVE; MULTIPLE MYELOMA; PARAPROTEINEMIAS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; WALDENSTROM MACROGLOBULINEMIA;

EID: 0033792783     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (156)

1. Mature myeloma cells are proliferative with self renewal potential
2. Transfer of myeloma plasma cells but not plasma cell depleted bone marrow and blood cells cause myeloma in healthy hosts
3. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell
4. A high frequency of circulating B cells share clonotypic IgH VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single cell and in-situ RT-PCR
5. + peripheral blood cells expressing CD38, CD56, and monotypic immunoglobulin light chain
6. Tumor cell heterogeneity in multiple myeloma: Antigenic, morphologic, and functional studies of cells from blood and bone marrow
7. Cellular origin and extent of clonal involvement in multiple myeloma: Genetic and phenotypic studies
8. Circulating clonotypic B cells in the biology of multiple myeloma: Speculations on the origin of myeloma
9. The blood B cells and bone marrow plasma cells in a patient with multiple myeloma include cells with the same N-ras mutation
10. + monoclonal B lineage cells in peripheral blood from myeloma patients as late stage B cells
11. + B lineage in Waldenstrom's macroglobulinemia
12. A high frequency of circulating B cells share clonotypic Ig heavy chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma as measured by single cell and in situ reverse transcriptase-polymerase chain reaction
13. Elevated plasma levels of soluble MUC1 epitope CA27.29 are associated with tumor burden in multiple myeloma patients
14. Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells
15. High numbers of clonal CD19+ cells in the peripheral blood of a patient with multiple myeloma
16. Phenotyping of circulating myeloma cells
17. Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug resistant disease in multiple myeloma
18. Deficient drug transporter function of bone marrow localized and leukemic plasma cells in multiple myeloma
19. Rationale for adjuvant vaccination after high-dose therapy for multiple myeloma
20. Karnofsky Lecture: Immunotherapy of lymphoma
21. Anti-B4-blocked ricin: A phase II trial of 7 day continuous infusion in patients with multiple myeloma
22. Treatment of plasma cell dyscrasias by antibody mediated immunotherapy
23. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody
24. Anti-CD38-blocked ricin: An immunotoxin for the treatment of multiple myeloma
25. Anti-CD54 (ICAM-1) has antitumour activity in SCID mice with human myeloma cells
26. Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24
27. MUC1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone
28. Anti-idiotype antibodies can induce long term complete remissions in non-Hodgkins lymphoma without eradicating the malignant clone
29. Improving antibody affinity by mimicking somatic hypermutation in vitro
30. Antigen specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs
31. B4, a human lymphocyte associated antigen expressed on normal, mitogen, and malignant B-lymphocytes
32. + is the common phenotype of myeloma cells
33. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation
34. Orderly expression of B cell antigens during the in vitro differentiation of nonmalignant human pre-B cells
35. Waldenstrom's macroglobulinemia
36. Immunophenotypic heterogeneity of multiple myeloma: Influence on the biology and clinical course of the disease
37. Pu.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes
38. Pu.1 recruits a second nuclear factor to a site important for immunoglobulin k 3' enhancer activity
39. Requirement of transcription factor Pu.1 in the development of multiple hematopoietic lineages
40. The hematopoietic transcription factor PU.1 is downregulated in human multiple myeloma cell lines
41. CD40 on human endothelial cells: Inducibility by cytokines and functional regulation of adhesion molecule expression
42. Interferon-upregulates CCR5 expression in cord and adult blood mononuclear phagocytes
43. Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma
44. Upregulation of MHC class II antigen on dendritic cells from hepatitis B virus transgenic mice by inteferon-gamma: Abrogation of immune response defect to a T-cell-dependent antigen
45. Interferon-gamma induces CD20 expression on multiple myeloma cells via induction of Pu.1 and augments Rituximab binding
46. Comparative pharmacokinetics of recombinant human gamma interferon after subcutaneous or intrapleural injection in malignant pleural effusion
47. A phase I trial of recombinant human interferon gamma in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS)
48. CD38: A multilineage cell activation molecule with a split personality
49. - progenitor cells
50. + human hematopoietic progenitor cells
51. ICAM-1 is a ligand for LFA-1-dependent adhesion of B, T and myeloid cells
52. The breast mucin Muc1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer
53. Muc1 synthetic peptide inhibition of intercellular adhesion molecule-1 and Muc1 binding requires six tandem repeats
54. CD54/ICAM-1 is a costimulator of NK cell mediated cytotoxicity
55. Primary structure of the leukocyte function-associated molecule-1 alpha subunit: An integrin with an embedded domain defining a protein superfamily
56. Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of [CAM-1 (CD54) and its regulation by glycosylation
57. Expression of cytoadhesion molecules (CD56, CD54, CD18, and CD29) by myeloma plasma cells
58. Expression of adhesion molecules on the endothelium of normal tissue vessels and vascular tumors
59. Adhesive interactions between tumour cells and bone marrow stromal elements in human multiple myeloma
60. Characterization of bone marrow stromal cells from multiple myeloma
61. Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies
62. Heparan sulfate proteoglycans from mouse mammary epithelial cells. Cell surface proteoglycans as a receptor for interstitial collagens
63. Cell surface proteoglycan binds mouse mammary epithelial cells to fibronectin and behave as a receptor on interstitial matrix
64. A novel laminin binding form of syndecan-1 produced by syndecan-1 cDNA transfected NIH-3T3 cells
65. Growth factors induce 3T3 cells to express bFGF binding syndecan
66. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1
67. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression
68. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia
69. Reed-Sternberg cells of classical Hodgkin's disease react with the plasma cell-specific monoclonal antibody B-B4 and express human syndecan-1
70. Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissues
71. Immunohistochemical localization of syndecan-1 in normal and pathological human uterine cervix
72. Suppression of syndecan-1 expression in endothelial cells by tumor necrosis factor-alpha
73. Rosenberg RD: Molecular cloning and expression of two distinct cDNAs encoding heparan sulfate proteoglycan core proteins from a rat endothelial cell line
74. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells
75. Antibody therapy for treatment of multiple myeloma
76. Extracellular matrix-dependent activation of syndecan-1 expression in keratinocyte growth factor treated keratinocytes
77. Syndecan-1 expression has prognostic significance in head and neck carcinoma
78. B-B2 and B-B4, two new mAb against secreting plasma cells
79. Characterization of anti-CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan-1 in human lymphoma cells
80. The epithelial mucin, Muc1, of milk, mammary gland and other tissues
81. Immunohistochemical characterization of a panel of 56 antibodies with normal human, small intestine, colon, and breast tissues
82. Expression of MUC1 core protein on multiple myeloma plasma cells permits selective binding to ICAM-1
83. Interleukin-6 in multiple myeloma and related plasma cell dyscrasias
84. Structure and expression of the human polymorphic epithelial mucin gene: An expressed VNTR unit
85. Expression of Muc1 on myeloma cells and induction of HLA unrestricted CTL against Muc1 from a multiple myeloma patient
86. 90Y anti-MUC1 antibodies
87. Use of murine monoclonal antibody for detection of circulating DF3 plasma antigen levels in breast cancer patients
88. Detection of polymorphic epithelial mucins in the serum of systemic breast cancer patients using the monoclonal antibody, NCRC- 11
89. Radioimmunodetection of human myeloma xenografts with a monoclonal antibody directed against a plasma cell specific antigen, HM1.24
90. Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells
91. Monoclonal antibody-based therapies of leukemia and lymphoma
92. Monoclonal antibody-based therapies for hematologic malignancies
93. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
94. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
95. Biologic and clinical evaluation of Rituxan in the management of newly diagnosed multiple myeloma patients
96. Antibody therapy for treatment of multiple myeloma
97. Rituximab therapy in previously treated Waldenstrom's macroglobulinemia: Preliminary evidence of activity
98. Phenotypic and clinical evidence supports Rituximab for Waldenstrom's macroglobulinemia
99. Rituximab is an active agent in Waldenstrom's macroglobulinemia
100. Natural history of HLA expression during tumor development
101. B7-1 expression by a non-antigen presenting cell-derived tumor
102. Regulation of immune responses by TGF-beta
103. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells
104. Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor
105. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation
106. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells
107. Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin
108. Adoptive T cell therapy
109. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant
110. Proliferating dendritic cell progenitors in human blood
111. + bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony stimulating factor, and TNF-alpha
112. Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity
113. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: Functional analysis
114. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes
115. Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus (KSHV) gene sequences
116. DNA-based immunization by in vivo transfection of dendritic cells
117. DNA immunization induces protective immunity against B-cell lymphoma
118. Induction of antitumor activity by immunization with fusion of dendritic and carcinoma cells
119. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity
120. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases
121. Vaccination of patients with B cell lymphoma using autologous antigen pulsed dendritic cells
122. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma
123. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses
124. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study
125. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
126. Idiotype vaccination in human myeloma: Generation of tumor-specific immune responses after high-dose chemotherapy
127. Eliciting hyperacute xenograft response to treat human cancer: Alpha (1,3) galactosyltransferase gene therapy
128. Broadened clinical utility of gene gun-mediated, granulocyte-macrophage colony-stimulating factor cDNA-based tumor cell vaccines as demonstrated with a mouse myeloma model
129. DNA vaccination against multiple myeloma
130. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma
131. Immune selection after antigen-specific immunotherapy of melanoma
132. Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T-cells
133. Interleukin-12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression
134. Intratumor injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model
135. In vivo adenoviral-mediated gene transfer of interleukin-2 in cutaneous plasmacytoma
136. Presentation of tumor antigens
137. Linking innate and adaptive immunity
138. Multiple myeloma/dendritic cell fusions as a vaccination strategy for myeloma
139. Autologous adoptive T cell transfer for a patient with plasma cell leukemia: Results of a pilot phase I trial
140. Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization
141. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes
142. Expression and regulation by interferon-gamma of the membrane bound complement regulators CD46, CD55 and CD59 in gastrointestinal tumours
143. Characterization of the complement regulatory proteins decay accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line
144. Expression of protectin (CD59) in human melanoma and its functional role in cell and complement mediated cytotoxicity
145. Levels of cell membrane CD59 regulate the extent of complement mediated lysis of human melanoma cells
146. Cytokines modulate expression of cell membrane complement inhibitory proteins in human lung cancer cell lines
147. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer
148. Constitutive expression of Fas ligand on multiple myeloma cells: A potential mechanism of tumor induced suppression of immune surveillance
149. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model
150. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage
151. Cancer-associated Muc-1 mucin inhibits human T-cell proliferation, which is reversible by IL- 2
152. A Muc1 mucin secreted from a colon carcinoma cell line inhibits target cell lysis by natural killer cells
153. Soluble MUC1 secreted by human epithelial cancer cells mediates immune suppression by blocking T cell activation
154. Soluble Muc-1 is elevated in multiple myeloma bone marrow plasma and inhibits T cell proliferation